ES2100632T3 - Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico. - Google Patents

Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico.

Info

Publication number
ES2100632T3
ES2100632T3 ES94307259T ES94307259T ES2100632T3 ES 2100632 T3 ES2100632 T3 ES 2100632T3 ES 94307259 T ES94307259 T ES 94307259T ES 94307259 T ES94307259 T ES 94307259T ES 2100632 T3 ES2100632 T3 ES 2100632T3
Authority
ES
Spain
Prior art keywords
alginate
agents
polyacrylic acid
interaction
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94307259T
Other languages
English (en)
Inventor
W R Gombotz
R J Mumper
L S Bouchard
A S Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Bristol Myers Squibb Co
Original Assignee
University of Washington
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Bristol Myers Squibb Co filed Critical University of Washington
Application granted granted Critical
Publication of ES2100632T3 publication Critical patent/ES2100632T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PERLAS DE ALGINATO SON EMPLEADAS COMO UN SISTEMA DE LIBERACION ORAL DE PUNTO ESPECIFICO PARA AGENTES CATIONICOS TERAPEUTICOS, TAL COMO TGF-(BETA)1, DESTINADAS A LOS AGENTES DEL PUNTO LUMINAL DEL INTESTINO DELGADO. LIBERACION MEJORADA DE MATERIAL BIOACTIVO SE OBTIENE POR: 1) INCORPORAR POLIANIONES ESCOGIDOS EN LAS PERLAS DE ALGINATO PARA PROTEGER LOS AGENTES TERAPEUTICOS CATIONICOS DE LA INTERACCION CON ALGINATO Y/O 2) TRATAMIENTO ACIDO DE PERLAS DE ALGINATO QUE CONTIENEN LOS AGENTES TERAPEUTICOS PARA REDUCIR EL PESO MOLECULAR DE ALGINATO Y SU INTERACCION CON LOS AGENTES. BIOACTIVIDAD MEJORADA DE AGENTES TERAPEUTICOS LIBERADOS DEL ALGINATO ES ATRIBUIDA A LA CAPACIDAD DE ACIDO POLIACRILICO PARA PROTEGER LOS AGENTES DE LA INTERACCION CON FRAGMENTOS MOLECULARES INFERIORES DE ALGINATO TRATADO CON ACIDO.
ES94307259T 1993-10-15 1994-10-04 Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico. Expired - Lifetime ES2100632T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/138,367 US5451411A (en) 1993-10-15 1993-10-15 Methods and compositions for the oral delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
ES2100632T3 true ES2100632T3 (es) 1997-06-16

Family

ID=22481704

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94307259T Expired - Lifetime ES2100632T3 (es) 1993-10-15 1994-10-04 Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico.

Country Status (9)

Country Link
US (1) US5451411A (es)
EP (1) EP0652015B1 (es)
JP (1) JPH07258115A (es)
AT (1) ATE150320T1 (es)
CA (1) CA2133271A1 (es)
DE (1) DE69402153T2 (es)
DK (1) DK0652015T3 (es)
ES (1) ES2100632T3 (es)
GR (1) GR3023307T3 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619660D0 (en) * 1996-09-20 1996-11-06 Scient Hospital Suppl Int Ltd Prevention of gastrointestinal damage
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
ATE443528T1 (de) * 1998-01-05 2009-10-15 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
GB9806530D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EP1117444A2 (en) * 1998-10-09 2001-07-25 The University Of Michigan Hydrogels and water soluble polymeric carriers for drug delivery
AU3556400A (en) 1999-03-17 2000-10-04 Novartis Ag Pharmaceutical compositions
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US7737108B1 (en) 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US6596310B1 (en) 2000-08-23 2003-07-22 Board Of Trustees Operating Michigan State University Method of artificial insemination by timed release of sperm from capsules or solid beads
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US20030206957A1 (en) * 2002-05-06 2003-11-06 Scherr George H. Orally administered medicament delivery systems
CA2515213A1 (en) * 2003-02-11 2004-08-26 University Of Washington Stimuli-responsive polymer conjugates and related methods
JP4822092B2 (ja) * 2003-09-01 2011-11-24 大正製薬株式会社 Ｗ／ｏ／ｗ型複合エマルション
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
US7744895B2 (en) 2005-08-31 2010-06-29 Yamanashi University Methods of treating allergies using TGF-β1 and allergens
WO2007109584A1 (en) * 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
WO2008004890A2 (en) 2006-07-04 2008-01-10 Spermvital As Preservation and controlled delivery/release of spermatozoa
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
DE102007059939A1 (de) 2007-12-12 2009-06-18 Müller-Schulte, Detlef, Dr. Auflösbare, magnetische und unmagnetische Polymerträger zur Abtrennung und Wiedergewinnung von Zellen und Biosubstanzen
IT1392471B1 (it) * 2008-11-25 2012-03-09 Pharmafilm S R L Collutorio in forma di sospensione stabile comprendente microsfere che incorporano un principio attivo.
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
WO2011152783A1 (en) * 2010-06-03 2011-12-08 Rph Pharmaceuticals Ab Formulations preserving bioactivity and methods of their preparation
US9165703B2 (en) * 2010-08-25 2015-10-20 Brown University Methods and systems for prolonged localization of drug delivery
US20120213856A1 (en) * 2011-02-23 2012-08-23 Po-Lun Wang Manufacturing Method of Microcapsule
CA2866170A1 (en) 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
EP3612196A4 (en) * 2017-04-18 2021-01-13 Actorius Innovations and Research Pvt. Ltd. Polymer based formulation for release of drugs and bioactives at specific git sites

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8323624D0 (en) * 1983-09-02 1983-10-05 Reckitt & Colmann Prod Ltd Medicinal compositions
DE3580384D1 (de) * 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US4923645A (en) * 1987-11-16 1990-05-08 Damon Biotech, Inc. Sustained release of encapsulated molecules
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent

Also Published As

Publication number Publication date
GR3023307T3 (en) 1997-08-29
EP0652015B1 (en) 1997-03-19
CA2133271A1 (en) 1995-04-16
DK0652015T3 (da) 1997-04-14
ATE150320T1 (de) 1997-04-15
EP0652015A2 (en) 1995-05-10
DE69402153D1 (de) 1997-04-24
US5451411A (en) 1995-09-19
JPH07258115A (ja) 1995-10-09
EP0652015A3 (en) 1995-08-02
DE69402153T2 (de) 1997-10-09

Similar Documents

Publication Publication Date Title
ES2100632T3 (es) Una composicion de liberacion controlada que comprende un alginato reticulado con cationes multivalentes combinado con un acido poliacrilico.
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
ES2088006T3 (es) Composiciones farmaceuticas osteoinductivas.
ES2185615T3 (es) Uso y liberacion controlada de las microcapsulas para estimular el crecimiento de la fibra nerviosa.
GB2261671B (en) Gel production from plant matter
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ES2070837T3 (es) Nuevas formulaciones de liberacion controlada de compuestos de tetraciclina.
MX9300977A (es) Compuetos heterobiciclicos.
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
NL300210I1 (nl) Humaan groeihormoon variant.
GT199800083A (es) Agonistas de prostaglandinas.
AR003984A1 (es) Composiciones antipruriticas, cosmeticas y/o farmaceuticas, procedimiento para su preparacion y empleo de dichas composiciones para la obtencion de unmedicamento.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
ZA876402B (en) Cosmetic composition
ES2073533T3 (es) Uso antivirico de composiciones que constan de acidos grasos esenciales e interferon.
MX18106A (es) Compuesto amidinicos y composiciones usadas para el tratamiento de pneumonia por pneumocystis carinii y otras enfermedades.
MX9306043A (es) Utilizacion de il-10 para evitar o tratar diabetes mellitus de pendiente de insulina.
IT8025159A0 (it) Preparato medicinale ad azione citostatica, nonche' derivati dell'acido isocianurico eprocedimento per la loro preparazione.
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
MX26167A (es) Derivados de acido piridil-benzoico para el tratamiento de enfermedades relacionadas con lecotrino.
ES2191189T3 (es) Procedimiento y composicion para el tratamiento antiparasitario del entorno de animales.
MX164619B (es) Composicion para el tratamiento de lesiones cutaneas
ES2052622T3 (es) Derivados de benzodioxol, compuestos que los comprenden y utilizacion de los mismos para la fabricacion de medicamentos.
ES2062329T3 (es) Composiciones anestesicas por via oral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652015

Country of ref document: ES